1.48 -0.01 (-0.67%) | 02-18 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.77 | 1-year : | 1.86 |
Resists | First : | 1.51 | Second : | 1.6 |
Pivot price | 1.46 | |||
Supports | First : | 1.38 | Second : | 1.15 |
MAs | MA(5) : | 1.48 ![]() |
MA(20) : | 1.47 ![]() |
MA(100) : | 1.62 ![]() |
MA(250) : | 1.58 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 52.3 ![]() |
D(3) : | 53.4 ![]() |
RSI | RSI(14): 47.3 ![]() |
|||
52-week | High : | 1.94 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IKNA ] has closed below upper band by 36.7%. Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.52 - 1.53 | 1.53 - 1.54 |
Low: | 1.45 - 1.46 | 1.46 - 1.47 |
Close: | 1.47 - 1.48 | 1.48 - 1.49 |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Tue, 11 Feb 2025
Ikena Oncology (NASDAQ:IKNA) Stock Price Down 0.7% - Here's Why - MarketBeat
Thu, 02 Jan 2025
US Penny Stocks To Watch In January 2025 - Simply Wall St
Mon, 23 Dec 2024
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewswire
Thu, 07 Nov 2024
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Tue, 28 May 2024
UPDATE – Ikena Oncology Announces Strategic Update - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 48 (M) |
Held by Insiders | 9.16e+006 (%) |
Held by Institutions | 4.5 (%) |
Shares Short | 110 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.358e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -9 % |
Return on Assets (ttm) | 755.2 % |
Return on Equity (ttm) | -22.1 % |
Qtrly Rev. Growth | 659000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -77.25 |
EBITDA (p.s.) | -8.31458e+007 |
Qtrly Earnings Growth | -1.3 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -62 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 0.25 |
Dividend | 0 |
Forward Dividend | 114860 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |